Delivery Order SPE2DB22D2206-SPE2DB25FJM98
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 MG, with a ceiling value of $13,338.54 under a firm fixed-price contract type. The delivery order was competitively awarded without set-aside provisions and has an ultimate completion date of August 4, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $8,443.61 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under the company's broader Indefinite Delivery Contract vehicle...
- The Defense Logistics Agency awarded a $5,730.89 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30-count bottles of Ondansetron ODT 4 mg tablets, with completion targeted for August 13, 2025. This non-set-aside contract was competitively awarded and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply arrangement with DLA. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $18,060.83 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units). This firm fixed-price delivery order, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $3,938.52 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is scheduled for completion by August 4, 2025, with performance at the contractor's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,730.96 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg on August 14, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, with performance occurring at the contractor's location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical suppliers. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,849.46 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg, with an ultimate completion date of August 11, 2025. This non-competitive delivery order was issued on August 8, 2025, with firm fixed pricing. The award represents a routine pharmaceutical procurement through AmerisourceBergen's established supply chain, with performance to be executed at the company's Conshohocken, Pennsylvania location. This...
- The Defense Logistics Agency awarded a delivery order valued at $14,466.96 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,736.12 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets in quantities of 30 units. This competitive award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJM98Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,523.43 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains operations as one of the nation's largest pharmaceutical distributors. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a prime pharmaceutical vendor for the Defense Health Agency and U.S. military medical supply chains, AmerisourceBergen supplies an extensive portfolio of medications and medical commodities across multiple therapeutic domains. The Ondansetron HCL delivery supports anti-nausea treatment needs within the military healthcare system, consistent with the company's role in fulfilling critical pharmaceutical requirements for federal medical procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.5k | 8/20/25 |